{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T22:25:24Z","timestamp":1782512724423,"version":"3.54.5"},"reference-count":10,"publisher":"Informa Healthcare","issue":"15","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1517\/14656566.9.15.2727","type":"journal-article","created":{"date-parts":[[2008,9,19]],"date-time":"2008-09-19T12:30:20Z","timestamp":1221827420000},"page":"2727-2731","source":"Crossref","is-referenced-by-count":26,"title":["Is rimonabant efficacious and safe in the treatment of obesity?"],"prefix":"10.1517","volume":"9","author":[{"given":"Sheila A","family":"Doggrell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3197","published-online":{"date-parts":[[2008,9,19]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-138-1-200301070-00008"},{"key":"CIT0002","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nn1457","volume":"8","author":"Di Marzo","year":"2005","journal-title":"Nat Neurosci"},{"key":"CIT0003","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/S0140-6736(05)66374-X","volume":"365","author":"Van Gaal","year":"2005","journal-title":"Lancet"},{"key":"CIT0004","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/jama.295.7.761","volume":"295","author":"Pi-Sunyer","year":"2006","journal-title":"JAMA"},{"key":"CIT0005","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1056\/NEJMoa044537","volume":"353","author":"Depr\u00e9s","year":"2005","journal-title":"N Engl J Med"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)69571-8"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61721-8"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-s258"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1001\/jama.299.13.1547"},{"key":"CIT0011","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1176\/ajp.2007.164.7.1035","volume":"164","author":"Posner","year":"2007","journal-title":"Am J Psychiatry"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.1517\/14656566.9.15.2727","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,18]],"date-time":"2017-06-18T11:53:33Z","timestamp":1497786813000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/full\/10.1517\/14656566.9.15.2727"}},"subtitle":["Evaluation of: Van Gaal L, Pi-Sunyer X, Depr\u00e9s JP, et al. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight\/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program. Diabetes Care 2008;31(Suppl 2):S229-40; and of Nissen SE, Nicholls SJ, Wolski K, et al. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease - the STRADIVARIUS randomized controlled trial. JAMA 2008;299:547-60"],"short-title":[],"issued":{"date-parts":[[2008,9,19]]},"references-count":10,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2008,9,19]]},"published-print":{"date-parts":[[2008,10]]}},"alternative-id":["10.1517\/14656566.9.15.2727"],"URL":"https:\/\/doi.org\/10.1517\/14656566.9.15.2727","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,9,19]]}}}